Visara Expands Ophthalmology Pipeline with Exclusive License for Neurotrophic Keratitis Therapy
October 14, 2026 — 06:25 CST
This Data Is Locked!
This area is available only to Subscribers.
Visara has acquired the global exclusive rights, excluding Greater China, in the ophthalmology field from Wuhan Haite Biopharma for HT006.2.2 to develop and commercialize. The... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
